Clinical Trials in Psychopharmacology (eBook)
406 Seiten
John Wiley & Sons (Verlag)
978-0-470-74917-3 (ISBN)
for many years, they are now the gold standard for judging whether
drugs are safe and useful. But should they be? What is the true
status of clinical trials? Even when they ostensibly demonstrate a
benefit of a certain treatment, the strict patient selection
criteria, poor compliance and high drop-out rate leave the
conclusions open to question. Are the new treatments really better
or more cost-effective than the old? Do they have fewer side
effects?
In this book the authors take a critical look at recent
developments and present a series of trenchant and challenging
observations. Section I examines the significant changes in law and
the regulatory environment that have occurred during the past ten
years. Has fossilization handicapped the US Food and Drug
Administration in promoting treatment advances? How can the
plethora of findings be regulated? This is particularly pertinent
in genomic studies and there are two chapters addressing the impact
of genomics on psychiatric research. This section also addresses
the role of women in drug trials - a group long excluded but
now demanding a part, for without testing how can optimal
treatments be devised?
The next two Sections highlight clinical trials in the major
areas of psychiatric pharmacological treatment, including Mood
Disorders, especially Bipolar, Anxiety Disorders, and addictions.
Chapters on pharmacological treatments for Eating Disorders,
Attention Deficit Disorder, Autism and Asperger's Syndrome,
and Impulse Control Disorder represent the latest thinking on these
subjects.
The final Section contains a consummate example of out-of-the
[Western]- box thinking, namely consideration of herbal medicines
- used by a large number of patients, with or without medical
supervision. We conclude with a close look at the problem of side
effects, then selected thoughts about methodology.
Clearly written, the text provides immediate access to new
developments across the spectrum of drug testing. Clinical
Trials in Psychopharmacology: A Better Brain is
provocative reading for psychiatrists, pharmacologists and all
those interested in improved drug treatments for patients with
mental illness.
* Raises questions about the conduct of trials and the
credibility of their outcomes that are relevant not just in
psychiatry but all areas of medicine
* Discusses the ethical problems in assessing outcomes in humans,
including children
Dr. Hertzman, a psychopharmacologist, previously Professor of Psychiatry at George Washington University, is now in private practice. Before that he was a Division Director for the National Institute on Alcohol Abuse and Alcoholism and served as their representative to the US government task force which originated US policy on clinical trials. His publications, in addition to the first edition of this book, include work on Mood Disorders, Anxiety, and Autism Spectrum Disorders. He has also been a Principal Investigator on clinical trials for more than thirty years. Dr Adler is the Owner/Director of Clinical Insights and Clinical Assistant Professor of Psychiatry at the University of Maryland. He is Board-certified in Psychiatry and Geriatric Psychiatry, and is a Certified Physician Investigator. From 1983 - 1998 he conducted research into the genetics and epidemiology of schizophrenia. He has been involved in clinical trials since 1993.
"this is a valuable addition to the monographs on clinical trial methodology and should be essential reading for all those undertaking trials of psychotropic drugs. The chapters are clearly written, the references are up-to-date and the volume comes at a price of under £50" (Human Psychopharmacology, 2010)
Erscheint lt. Verlag | 16.3.2010 |
---|---|
Sprache | englisch |
Themenwelt | Medizin / Pharmazie ► Gesundheitsfachberufe |
Medizin / Pharmazie ► Medizinische Fachgebiete ► Pharmakologie / Pharmakotherapie | |
Medizin / Pharmazie ► Medizinische Fachgebiete ► Psychiatrie / Psychotherapie | |
Schlagworte | Biological psychiatry • Biologische Psychiatrie • Clinical Pharmacology & Therapeutics • Klinische Pharmakologie u. Therapie • Medical Science • Medizin • Neurologie • Psychiatrie • Psychopharmacology • Psychopharmaka • Psychopharmakologie • Substance Misuse • Substanzmissbrauch |
ISBN-10 | 0-470-74917-2 / 0470749172 |
ISBN-13 | 978-0-470-74917-3 / 9780470749173 |
Haben Sie eine Frage zum Produkt? |
Größe: 1,8 MB
Kopierschutz: Adobe-DRM
Adobe-DRM ist ein Kopierschutz, der das eBook vor Mißbrauch schützen soll. Dabei wird das eBook bereits beim Download auf Ihre persönliche Adobe-ID autorisiert. Lesen können Sie das eBook dann nur auf den Geräten, welche ebenfalls auf Ihre Adobe-ID registriert sind.
Details zum Adobe-DRM
Dateiformat: PDF (Portable Document Format)
Mit einem festen Seitenlayout eignet sich die PDF besonders für Fachbücher mit Spalten, Tabellen und Abbildungen. Eine PDF kann auf fast allen Geräten angezeigt werden, ist aber für kleine Displays (Smartphone, eReader) nur eingeschränkt geeignet.
Systemvoraussetzungen:
PC/Mac: Mit einem PC oder Mac können Sie dieses eBook lesen. Sie benötigen eine
eReader: Dieses eBook kann mit (fast) allen eBook-Readern gelesen werden. Mit dem amazon-Kindle ist es aber nicht kompatibel.
Smartphone/Tablet: Egal ob Apple oder Android, dieses eBook können Sie lesen. Sie benötigen eine
Geräteliste und zusätzliche Hinweise
Zusätzliches Feature: Online Lesen
Dieses eBook können Sie zusätzlich zum Download auch online im Webbrowser lesen.
Buying eBooks from abroad
For tax law reasons we can sell eBooks just within Germany and Switzerland. Regrettably we cannot fulfill eBook-orders from other countries.
aus dem Bereich